Reprogrammed Platelets: Effectors of Thrombosis in Metabolic Syndromes

重编程血小板:代谢综合征中血栓形成的效应器

基本信息

  • 批准号:
    8656415
  • 负责人:
  • 金额:
    $ 261.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-05-01 至 2017-04-30
  • 项目状态:
    已结题

项目摘要

The broad objective of the University of Utah Molecular Medicine Translation Research Center in Thrombosis (U2M2-TRCT) is to dissect novel clinical and molecular determinants of thrombotic risk in patients with metabolic disorders (obesity, diabetes, and the metabolic syndrome). The U2M2-TRCT unites a group of basic and clinical investigators with breadth and expertise in thrombosis and metabolic dysregulation. Our studies will test the thematic hypothesis that metabolic changes in the systemic milieu reprogram platelet precursors and platelets themselves, resulting in altered thrombotic activities of these critical cells. To examin this central theme, we propose four research projects and four cores and studies by a cadre of established and emerging investigators with proven track records of productive interactions. The intellectual infrastructure is as follows: Project 1, The Molecular Regulation of Platelet Reprogramming by the Metabolic Milieu, characterizes reprogramming events in platelets and dissects the mechanisms by which microRNAs influence platelet phenotypes in metabolic syndromes; Project 2, Metabolic Regulation of Platelet Reprogramming, will determine how genetic manipulation of glucose transporters and modulators of mitochondrial function regulate reprogramming events and functional activities of platelets; Project 3, The Role of the Metabolic Milieu in Regulating Platelet Reprogramming in Humans, prospectively examines platelet reprogramming and platelet hyperreactivity imposed by the metabolic milieu of type 2 diabetes. Project 3 will also determine if therapeutic correction of metabolic imbalances reverses platelet reprogramming and hyperactivity; Project 4, Platelet Reprogramming in Human Obesity and Diabetes, will evaluate platelet reprogramming and function in subjects exposed to acute triglyceride emulsion infusion, obese subjects before and after bariatric surgery, and patients enrolled in the Framingham Heart Study. Screening of an early-phase translation mRNA nanochip in humans with metabolic syndromes is a key feature in Project 4. Together, our translational studies will explore new paradigms in thrombosis and metabolic syndromes, and will be a unique platform for research career development.
犹他大学分子医学血栓翻译研究中心(U2M2-TRCT)的广泛目标是分析代谢紊乱(肥胖、糖尿病和代谢综合征)患者血栓形成风险的新的临床和分子决定因素。U2M2-TRCT联合了一组在血栓形成和代谢失调方面具有广度和专业知识的基础和临床研究人员。我们的研究将测试这一主题假设,即系统环境中的新陈代谢变化对血小板前体和血小板本身进行重新编程,导致这些关键细胞的血栓活性改变。为了审查这一中心主题,我们提出了四个研究项目和四个核心,并由一批成熟的和新出现的调查人员进行研究,这些调查人员具有经过证明的生产性互动的记录。其智力基础如下:项目1“代谢环境对血小板重编程的分子调控”描述了血小板中的重编程事件,并剖析了microRNA影响代谢综合征中血小板表型的机制;项目2“血小板重编程的代谢调控”将确定对葡萄糖转运体和线粒体功能调节剂的遗传操作如何调节血小板的重编程事件和功能活动;项目3“代谢环境在调节人类血小板重编程中的作用”,前瞻性地检查了2型糖尿病的代谢环境引起的血小板重编程和血小板高反应性。项目3还将确定代谢失衡的治疗纠正是否逆转了血小板重新编程和过度活动;项目4,人类肥胖和糖尿病中的血小板重新编程,将评估暴露于急性甘油三酯乳剂输注的受试者、肥胖受试者在减肥手术前后以及参加Framingham心脏研究的患者的血小板重新编程和功能。在代谢综合征患者中筛选早期翻译mRNA纳米芯片是项目4的一个关键特征。我们的翻译研究将共同探索血栓形成和代谢综合征的新范式,并将成为研究生涯发展的独特平台。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew S Weyrich其他文献

DECREASED TRANSENDOTHELIAL CELL MIGRATION IN NEONATES IS ASSOCIATED WITH DELAYED EXPRESSION OF P-SELECTION. ▴ 1754
  • DOI:
    10.1203/00006450-199604001-01778
  • 发表时间:
    1996-04-01
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Michael K Garyer;Andrew S Weyrich;Wenhua Li;Diane E Lorant
  • 通讯作者:
    Diane E Lorant

Andrew S Weyrich的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew S Weyrich', 18)}}的其他基金

Translational Control of Megakaryocyte and Platelet Gene Expression in Disease
疾病中巨核细胞和血小板基因表达的转化控制
  • 批准号:
    10616557
  • 财政年份:
    2019
  • 资助金额:
    $ 261.08万
  • 项目类别:
Translational Control of Megakaryocyte and Platelet Gene Expression in Disease
疾病中巨核细胞和血小板基因表达的转化控制
  • 批准号:
    10569253
  • 财政年份:
    2019
  • 资助金额:
    $ 261.08万
  • 项目类别:
2014 Hemostasis Gordon Research Conference and Gordon Research Seminar
2014止血戈登研究会议暨戈登研究研讨会
  • 批准号:
    8784662
  • 财政年份:
    2014
  • 资助金额:
    $ 261.08万
  • 项目类别:
Patient Enrollment and Data Analysis
患者登记和数据分析
  • 批准号:
    8464249
  • 财政年份:
    2013
  • 资助金额:
    $ 261.08万
  • 项目类别:
Platelet Reprogramming in Human Obesity and Diabetes
人类肥胖和糖尿病中的血小板重编程
  • 批准号:
    8464247
  • 财政年份:
    2013
  • 资助金额:
    $ 261.08万
  • 项目类别:
Administrative
行政的
  • 批准号:
    8391960
  • 财政年份:
    2012
  • 资助金额:
    $ 261.08万
  • 项目类别:
Platelet Reprogramming in Human Obesity and Diabetes
人类肥胖和糖尿病中的血小板重编程
  • 批准号:
    8391959
  • 财政年份:
    2012
  • 资助金额:
    $ 261.08万
  • 项目类别:
Reprogrammed Platelets: Effectors of Thrombosis in Metabolic Syndromes
重编程血小板:代谢综合征中血栓形成的效应器
  • 批准号:
    8464229
  • 财政年份:
    2012
  • 资助金额:
    $ 261.08万
  • 项目类别:
Reprogrammed Platelets: Effectors of Thrombosis in Metabolic Syndromes
重编程血小板:代谢综合征中血栓形成的效应器
  • 批准号:
    9068226
  • 财政年份:
    2012
  • 资助金额:
    $ 261.08万
  • 项目类别:
Human and Mouse Cell Isolation and Phenotyping
人类和小鼠细胞分离和表型分析
  • 批准号:
    8391963
  • 财政年份:
    2012
  • 资助金额:
    $ 261.08万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 261.08万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 261.08万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 261.08万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 261.08万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 261.08万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 261.08万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 261.08万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 261.08万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 261.08万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 261.08万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了